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The magnitude of the global human immunodeficiency virus (HIV)
epidemic is determined by women from lower income countries,
specifically sub-Saharan Africa. Microbicides offer women who are
unable to negotiate safe sex practices a self-initiated HIV preven-
tion method. Of note, is its potential to yield significant public
health benefits even with relatively conservative efficacy, coverage
and user adherence estimates, making microbicides an effective
intervention to invest scarce healthcare resources. Existing
healthcare delivery systems provide an excellent opportunity to
identify women at highest risk for infection and to also provide an
access point to initiate microbicide use. Innovative quality
improvement approaches, which strengthen existing sexual
reproductive health services and include HIV testing, and linkages
to care and treatment services, provide an opportunity to lay the
foundations for wide-scale provision of microbicides. The potential
to enhance health outcomes in women and infants and potentially
affect rates of new HIV infection may soon be realised.
 2012 Elsevier Ltd. All rights reserved.
Introduction
Women feature more strongly in this decade of the HIV pandemic than the previous two. Young
women in sub-Saharan Africa1 and in the USA2 are disproportionately affected by human immuno-
deficiency virus (HIV) compared with their male counterparts. More than one-half of all global HIV
infections are in women infected primarily through sexual transmission.
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Women’s vulnerability to HIV infection is a result of a complex interplay of social, cultural, bio-
logical, political and economic factors.3 Current HIV prevention options are mainly dependent on male
partner co-operation. Power disparities between men and women limit the ability of women to
negotiate safer sex practices, and this is particularly pronounced for young women under 20 years of
age.4,5 In the absence of an effective vaccine, other approaches that reduce new HIV infections, even if
moderately effective, are urgent.6
To this end, investment in the development of microbicides has occurred over the past 17 years, and
efforts are designed to enable women to control their HIV risk through a self-initiated method. The
CAPRISA 004, 1% tenofovir gel trial7 provided the first evidence that such a technology was within our
reach. This antiretroviral agent specifically formulated for topical application in the female genital tract
has limited systemic toxicities. If effectiveness is confirmed in the FACTS 001 trial,8,9 tenofovir gel may
fill an important HIV prevention gap for women in the next 3–5 years. Mathematical modelling data
based on the CAPRISA 004 trial findings,7,10 indicates that, over 20 years, the use of tenofovir gel in
South Africa alone could avert up to 2 million new infections and 1 million deaths from acquired
immune deficiency syndrome (AIDS), which would significantly affect the epidemic in South Africa.10
Tenofovir gel use in more than 25% of sexual encounters could significantly alter the course of the
epidemic in southern Africa, and thereby globally.
Further down the microbicide development pipeline, we anticipate additional products with
greater efficacy through enhanced drug-delivery mechanisms such as vaginal rings, sustained-release
formulations, synergistic drug combinations,11 and multi-purpose technologies that, for example,
combine fertility control and HIV risk-reduction needs. Antiretroviral-basedmicrobicides are now seen
as the future of HIV control.12
It is at this critically important stage, and before product licensure, that we ask the difficult
implementation questions. These include determining the potential barriers to access and uptake, and
how to best incorporate this prevention strategy into existing healthcare delivery systems to maximise
access to women in resource-limited settings who can benefit most from such technologies
expeditiously.13,14
Do microbicides meet the criteria for an effective intervention?
Resources for meeting healthcare needs in low-income countries are limited. Introduction of new
technologies and innovations have to be cognisant of this, and careful attention needs to be paid to
criteria used to determine public health benefits of new interventions for optimal, efficient and
effective use of limited resources.14
Given the recent advances in evidence-based HIV prevention approaches to reduce sexual trans-
mission of HIV and the diversity of HIV epidemics geographically, populations at risk, levels of efficacy
and healthcare delivery infrastructure,15 Shelton16 proposed a useful framework comprising 20 criteria
to guide decision-making on use of scarce health resources in developing countries.16We have adapted
this guide to assess if microbicides have the potential to meet the criteria for an effective intervention.
The criteria used are presented in Table 1.16
Potential barriers and models for implementing microbicides in low-income countries
The microbicide development pipeline is in various stages of testing of different candidate products
ranging from the pre-clinical stage to phase 1 to 3 studies.17 Several immediate barriers exist for
implementation (Fig. 1). The first major barrier to be overcome is the identification of a safe and
effective candidate agent. Thus far, only one microbicide trial has been successful in proving effec-
tiveness. After establishing effectiveness, the regulatory pathway will require in-country licensing and
registration of the candidate agent. It is unclear how lengthy this process will be. Health systems from
lower income countries will also need to absorb the human resource and infrastructure requirements
of microbicide provision. Use of innovative approaches such as quality improvement approaches
(described later) needs to be part of health systems’ strategic planning efforts. Lastly, sustained
production of microbicides will require long-term investment and possibly in-country capacity for
production.
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Translating positive findings from rigorous, small-scale, randomised-controlled trials into large-
scale healthcare systems in low-income countries poses many challenges.18 Model predictions for
the variability in performance of prevention of mother-to-child transmission protocols, using hypo-
thetical and reported data, demonstrate that highly effective combination antiretroviral treatment will
only be marginally more effective than single-dose antiretroviral drugs unless health systems achieve
high performance at each interaction in the prevention of mother-to-child transmission pathway.19 A
similar threat exists for scale-up of effective microbicides without pre-emptive planning and
preparation.
Health systems in developing countries are without doubt under severe strain from human
resources, infrastructure and budgetary deficiencies,20 and exacerbated by advancing HIV disease and
concomitant co-morbidities. A glimpse of this challenge was gleaned in the provision of antiretroviral
treatment. Notwithstanding these challenges, existing health systems remain the main mechanism to
close the evidence–implementation gap,21 and the only sustainable way to efficiently introduce
microbicides for wide and effective coverage that translates into public health benefits.
Table 1
Criteria for an effective human immunodeficiency virus prevention microbicide intervention.
Criterion Comment
Health burden in low-income
countries
High HIV burden; HIV prevention is a health priority; women younger than 24years
have three- to six-fold higher rates of HIV infection compared with men.
Individual efficacy First trial with tenofovir gel shows 39% effectiveness, but could be as high 54% with
higher adherence. Most trials aim for at least 50% higher efficacy than placebo.
Scalability Will benefit individual and reach scale by reducing transmissions within sexual
networks.
Low cost Cost issues will exist at initial production but likely to be reduced over time.
Simplicity Fairly simple to administer but requires training at initiation and HIV and pregnancy
requires on-going monitoring.
Safety Safe with low systemic absorption; anticipate a good risk – benefit profile.
User acceptability Microbicides have high user acceptability in trial settings; unable to date to test in real-
world settings.
Family acceptability Can be used without partner knowledge; some data available to support family
acceptability.
Social norms Limited community level data available that support microbicides. Advocacy efforts
need to be strengthened.
Provider/medical culture Motivation to avert HIV infection is high in countries burdened with disease.
Potential for integration Excellent potential for integration into existing services, particularly sexual
reproductive health and pre- and post-natal services.




Regulators such as the US Food and Drug Administration have agreed to fast-track
microbicide candidates for registration; need sufficient efficacy and safety data for
licensure; at least one other confirmatory trial; FACTS 001 is under way to confirm
CAPRISA 004.7
Procurement and logistics Many low-income countries gaining experience with antiretroviral treatment and
preventing mother-to-child transmission scale-up; systems are in place to address this;
the South African government holds royalty-free license and is already exploring
manufacturing options, market stratification and access across Africa.
Timing dependency Only coitally administrated use has been tested to date; in the future we are likely to
have multiple formulations and delivery vehicles, including vaginal rings and multi-
purpose technologies.
Durability Low durability; will need to be provided repeatedly; frequency could vary in the future
based on formulation and delivery vehicle.
Behaviour dependency A challenge; needs to be incorporated into current behaviour; new method that will
need intense support initially and less with time.
Commercial sector
compatibility
Potential for socially responsible private–public partnerships; already in place in South
Africa.
Collateral benefits Reduce maternal morbidity and mortality; avert infants infections, other sexually
transmitted infection and enhance sexual and reproductive health services; women
empowerment.
Sustainability Requires ongoing commitment and investment.
HIV, human immunodeficiency virus; adapted from Shelton 2011.16
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Implementation science is defined as ‘the scientific study of methods to promote the integration of
research findings and evidence-based interventions into healthcare policy and practice and hence
improve the quality and effectiveness of health services and care.’22 By definition, this type of
engagement provides an appropriate framework for investigating the barriers to integration of new
prevention methods into existing health systems, and develop innovative methodologies, such as the
quality improvement approach to address challenges.
Thus far, the benefits of medical advances especially in developing countries have been held
‘hostage’ to our inability to bring to scale what we knowworks. Often, policies are formulated but little
attention is paid to programmatic scale-up, training and support of healthcare providers, existing
workloads, the diversity of needs in different healthcare settings that demand critical thinking, and
troubleshooting on a day-to-day, client-to-client basis. One strategy to address this gap is the quality
improvement approach. The quality improvement approach is premised on designing systems for
maximum effectiveness, efficiency, and adaptability, and to actively disseminate the best models for
health-service delivery at a rapid rate. Quality improvement aims to strengthen heath systems using
small-scale, rapid cycles of improvement that are designed and implemented by local providers to
develop reliable processes for service delivery through mentored coaching, re-enforcement and
support.23–25 Using this approach, and with minimal additional resources, existing services could be
substantially strengthened to introduce microbicides at scale. Importantly, individual skills-building
acquired through the quality-improvement approach include critical thinking and problem solving
that can have application to other system challenges. Application of the quality improvement approach
to health systems of low-income countries has been tested and shows considerable potential. In South
Africa, rapid scale-up of access to HIV care and treatment services,26 and reduced rates of mother-to-
child transmission of HIV at a district level owing to improved coverage,27 have been demonstrated.
In order for women to benefit fromHIV prevention interventions such as microbicides, it is critically
important to be able to identify those uninfected and at high risk for infection.15 Existing healthcare
infrastructure and human resources, such as those listed in Table 2, provides rational, extant and often
overlooked opportunities for identification of at-risk women and also programmatic scale-up of
microbicides and other combination prevention methods. Low-income countries are already investing
heavily in test and treat campaigns, and it is critical to be able to capitalise on these opportunities as
potential platforms from which microbicides can be launched.
Fig. 1. Immediate barriers to implementing microbicides in low-income countries. HIV, human immunodeficiency virus; HSV2,
herpes simplex virus 2.
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Using the public sector family planning clinic model as a prototype for incorporation of micro-
bicides provision, several advantages are immediately apparent: (1) large numbers of sexually active
women already using regular, long-term, family planning services become accessible; (2) staff at the
family planning clinics are trained on reproductive health and have prior knowledge and experience
with adherence to medication support and counselling; (3) family planning clinics are often integrated
in primary healthcare clinics that provide a minimum package of health services at no cost, and are
widely available in South Africa; (4) family planning services, in addition to provision of contraception,
also provide womenwith a sexual and reproductive health package that can include HIV risk reduction
counselling, HIV testing, sexually transmitted disease screening, condom provision and pap smears
Similar opportunities exist in pre-natal and post-natal clinic services.
Other concerns relating to scale up of antiretroviral agents used prophylactically, either in oral or
topical formulations, relate to the potential for long-term, drug-adverse effects, emergence of drug
resistance, adherence challenges that widen the efficacy-effectiveness gap and behavioural disinhi-
bition. Currently, no clear evidence supports any of these potential concerns as reasons to halt
development. It is critically important, however, that further opportunities for assessing these
concerns are maximised in future research. These include careful monitoring of seroconvertors from
prevention trials, natural-history studies that monitor drug resistant strains of virus, and study of
disease progression and therapeutic outcomes once initiated on antiretroviral treatment. As with all
new technologies, adherence support at initiation is more intensive and, over time, with greater
product experience and confidence in effectiveness, adherence may be easier to facilitate. Post-trial
access studies provide excellent opportunities to better understand these issues in a real-world setting.
Conclusion
Low-income countries bear a disproportionate burden of HIV infection. In sub-Saharan Africa, the
HIV epidemic is of a generalised nature. Young women in these countries have three- to six-fold higher
rates of HIV infection compared with men in the same age range, and have multiple sexual and
reproductive health needs in addition to their HIV risk. Microbicides are promising new women-
initiated prevention technology. The CAPRISA 004, 1% tenofovir gel is an important first step in
enhancing optimism in the microbicide development field. The confirmatory FACTS 001 trial could
potentially lead to licensure of tenofovir gel in South Africa in the next 2–3 years. Modelling estimates
indicate that a substantial number of HIV infections will be averted in South Africa even with
a moderately effective product, used at least in one-quarter or more of all sex acts.
We provide a framework to evaluate the utility of microbicides as a public health tool. Additionally,
we explore the product-development pathway and health-system barriers to access to a microbicide.
We propose the use of innovative implementation sciences approaches, including the quality-
improvement approach to strengthen health systems and roll out a new intervention for public
health benefit. We submit that using existing points of care, such as family planning clinics, to assess
HIV risk will reduce missed opportunities to engage women at high risk for infection. The potential to
initiate women on microbicides, when these become available, is enhanced by using existing services,
infrastructure and human resources.
Table 2
Potential operational model entry points for microbicides scale up.
Existing model Missed opportunities.
Family planning clinic within a
primary healthcare clinic
Contraception provision; PAP smear; condom provision.
Primary healthcare clinic general Well-baby immunisation clinics; antenatal clinic; postnatal clinic; sexually
transmitted infection treatment; condom provision.
Antiretroviral clinics HIV screening.
Retail pharmacy Contraceptive dispensing; HIV screening; sexually transmitted infection drug
dispensing; pregnancy testing or test kit purchase; condom sale.
HIV, human immunodeficiency virus.
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It is likely with continued investments in microbicide development that the future will bring many
more microbicide products with more convenient formulations and drug-delivery mechanisms to
meet the multiple sexual and reproductive health needs of women. Now is the time to start to explore
how to introduce these new technologies efficiently and effectively to women and ensure that history
is not repeated by our inability to deliver expeditiously what we know works to those who need it
most.
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